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Abstract
Inflammatory diseases of the respiratory system such as rhinosinusitis, chronic obstructive
pulmonary disease, or bronchial asthma are strongly associated with overproduction and
hypersecretion of mucus lining the epithelial airway surface. 1,8-cineol, the active ingredient
of the pharmaceutical drug Soledum, is commonly applied for treating such inflammatory
airway diseases. However, its potential effects on mucus overproduction still remain
unclear.In the present study, we successfully established ex vivo cultures of human nasal
turbinate slices to investigate the effects of 1,8-cineol on mucus hypersecretion in experi-
mentally induced rhinosinusitis. The presence of acetyl-α-tubulin-positive cilia confirmed
the integrity of the ex vivo cultured epithelium. Mucin-filled goblet cells were also detectable
in nasal slice cultures, as revealed by Alcian Blue and Periodic acid-Schiff stainings. Treat-
ment of nasal slice cultures with lipopolysaccharides mimicking bacterial infection as
observed during late rhinosinusitis led to a significantly increased number of mucin-filled
goblet cells. Notably, the number of mucin-filled goblet cells was found to be significantly
decreased after co-treatment with 1,8-cineol. On a molecular level, real time PCR-analysis
further showed 1,8-cineol to significantly reduce the expression levels of the mucin genes
MUC2 and MUC19 in close association with significantly attenuated NF-κB-activity. In con-
clusion, we demonstrate for the first time a 1,8-cineol-dependent reduction of mucin-filled
goblet cells and MUC2-gene expression associated with an attenuated NF-κB-activity in
human nasal slice cultures. Our findings suggest that these effects partially account for the
clinical benefits of 1,8-cineol-based therapy during rhinosinusitis. Therefore, topical applica-
tion of 1,8-cineol may offer a novel therapeutic approach to reduce bacteria-induced mucus
hypersecretion.
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Introduction
The clearance of mucus represents a primary defense mechanism within mammalian airways,
providing a protective barrier against pathogens and toxins [1]. Overproduction and hyperse-
cretion of mucin are common symptoms of inflammatory diseases, such as rhinosinusitis,
chronic obstructive pulmonary disease (COPD) [2, 3] or asthma [4]. As a mixture of water,
ions, glycoproteins, and lipids, mucus coats the apical epithelial surface of the human respira-
tory tract. Mucosal components are secreted by goblet cells in polarized epithelium and by
secretory cells in the submucosal glands (SMG) [5]. The major macromolecular constituents of
epithelial mucus are mucins, which are large, highly glycosylated, viscoelastic macromolecules.
Mucin glycoproteins are particularly involved in organizing the structure of the mucus and
mainly contribute to its rheological properties [6, 7]. Likewise, mucin overproduction is
strongly associated to inflammatory diseases, like rhinosinusitis [8], cystic fibrosis [9], chronic
bronchitis [10] or asthma [11, 12].
Medical treatment of inflammatory diseases of the human respiratory tract may involve
1,8-cineol, the active ingredient of the clinically-accredited medical product Soledum.
1,8-cineol was identified by Cloez in the 1870s as the major constituent of Eucalyptus globulus
essential oil [13] and possesses both anti-microbial [14] and anti-inflammatory properties [15,
16]. In 2005, Inoue and colleagues demonstrated 1,8-cineol to partially reduce airway inflam-
mation in a mouse model of allergic asthma [17]. Accordingly, placebo-controlled double-
blind trials impressively showed the beneficial anti-inflammatory activity of 1,8-cineol for
treating inflammatory diseases, as in rhinosinusitis [18], bronchial asthma [19], and COPD
[20]. Despite these promising findings, a direct linkage between the anti-inflammatory activity
of 1,8-cineol and mucus production as a hallmark of inflammatory diseases remains
undetermined.
Facing these challenges, we aimed to establish an ex vivo culture system for human nasal
turbinate tissue to investigate the potential effects of 1,8-cineol on mucus hypersecretion dur-
ing experimentally induced rhinosinusitis. Although mouse models of rhinosinusitis [21, 22],
cultured primary human airway epithelial cells, or human bronchial explants [23] are com-
monly used to model and mimic inflammation, these models may not fully reflect the complex
pathology of diseased human nasal tissue. In the present study, nasal epithelia were successfully
cultivated ex vivo and retained their integrity, including the presence of mucin-filled goblet
cells. Notably, treatment of nasal slice cultures with lipopolysaccharides (LPS) mimicking bac-
terial infection common during late rhinosinusitis was associated with a significantly increased
number of mucin-filled cells. A co-treatment with 1,8-cineol led to a significantly attenuated
density of this specific cell type. Accordingly, 1,8-cineol-treatment resulted in a significantly
reduced expression of the mucin genes MUC2 and MUC19 levels in a close association with
attenuated activity of NF-κB. Our findings suggest the role of 1,8-cineol in reducing mucus
overproduction to contribute to the beneficial effects of 1,8-cineol-based therapeutic
approaches.
Material and Methods
Human Material
Human nasal turbinate specimens (middle and inferior turbinates) were obtained from
patients during minimal-invasive surgery after informed written consent and according to the
principles of the Declaration of Helsinki (1964) and local and international guidelines (Bezirks-
regierung Detmold/Münster). Fifty percent of the patients were pre-treated with decongestant
spray containing Xylometazolin (Nasic, pharmacological half-life of 12h, Klosterfrau
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Healthcare Group) prior to obtaining nasal inferior turbinate tissue. Isolation and further
experimental procedures were ethically approved by the ethics commission of the Ärztekam-
mer Westfalen-Lippe and the medical faculty of the Westfälische Wilhems-Universität (Mün-
ster, Germany) (approval reference number 2012-15-fS).
Tissue culture
Specimens obtained during surgery were directly placed on ice in Dulbecco modified Eagle
medium (PAA, Pasching, Austria) supplemented with penicillin and streptomycin. For tissue
culture, specimens were sliced (200μm thickness) using McIlwain tissue chopper (Ted Pella,
Inc., Redding, CA) before being transferred to culture plate inserts comprising a 0.4 μm nitro-
cellulose membrane (Millipore/Greiner, Billerica, MA, USA). Slice-containing membranes
were placed at the interface of air and B-ALI differentiation medium (Lonza, Basel, Switzer-
land) within respective cell culture well-plates (TPP Techno Plastic Products, Trasadingen,
Austria) and DMEMHigh Glucose (Biochrom, Berlin, Germany) followed by culture in a
humidified incubator (Binder, Tuttlingen, Germany) at 37°C and 5% CO2. Nasal slices were
cultured for up to 4 weeks and fed every two days by replacing the medium with fresh B-ALI
differentiation medium.
Human nasal slices cultivated for 7 days were treated with LPS (100 ng/ml, rough strains
from Salmonella enterica Re 595, cat. no. L9764, Sigma-Adrich St. Louis, MO, USA) or LPS
and 1,8-Cineol (10−5 M, Klosterfrau Healthcare Group, Cassella-med GmbH & Co. KG,
Cologne, Germany as described in [24] for 60 minutes followed by respective stainings or real
time PCR.
Immunohistochemistry
Nasal slice cultures were fixed using 4% formalin, treated with water for 60 minutes and dehy-
drated and embedded by applying 50% EtOH, 75% EtOH, 95% EtOH, 100% EtOH, Xylol and
Xylol:Paraplast (1:1, Leica Biosystems Nussloch GmbH, Nussloch, Germany) for 60 minutes
each followed by application of Paraplast over night. Afterwards, 2 μm thick sections were pre-
pared. Prior to immunohistochemistry, sections were deparaffinized in Xylene and afterwards
rehydrated in 100% EtOH for 3 minutes, 95% EtOH for 3 minutes and 70% EtOH for 3 min-
utes followed by application of distilled water.
Alternatively, 10 μm thick cryostat sections were prepared from nasal slices cultures and
inferior turbinate tissue followed by fixation using 4% paraformaldehyde for 20 min at RT
prior to immunohistochemistry.
Blocking was performed using 5% goat serum for 30 minutes followed by incubation with
primary rabbit anti-acetyl-α-tubulin antibody (1:800, Cell Signaling Technology, Danvers,
MA, USA), anti-Caspase 3 antibody (1:500, Cell Signaling) or anti-p65 antibody (Santa Cruz
Biotechnology, Heidelberg, Germany) for 2 hours at RT. Secondary fluorochrome-conjugated
antibody (goat anti rabbit conjugated with Alexa 555, 1:300; Molecular Probes, Göttingen, Ger-
many) applied for 1 hour at room temperature (RT). Nuclear counterstaining was performed
using SYTOX green (1:20000, Invitrogen, Carlsbad, CA, USA) for 30 minutes at RT. Fluores-
cence imaging was performed using confocal laser scanning microscopy (LSM 510, Carl Zeiss,
and DM IRB, Leica, Wetzlar, Germany).
Staining
Cultured nasal slices were embedded in paraffin and sectioned as described above. For Hema-
toxylin and Eosin (HE) staining sections were deparaffinized in Xylene and afterwards rehy-
drated in 100% EtOH for 3 minutes, 95% EtOH for 3 minutes and 70% EtOH for 3 minutes.
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After rinsing the sections in distilled water, Mayer’s alum haematoxylin was applied for 5 min-
utes and rinsed in running tap water. Afterwards, sections were stained for 2 minutes using 2%
Eosin solution and immersed once in water. Sections were dehydrated by rinsing in 70% Etha-
nol for 3 minutes, 90% Ethanol for 3 minutes and two times 100% Ethanol for 3 minutes each.
Finally, the slides were cleared using Xylene and mounted in Entellan.
For Alcian Blue staining sections were deparaffinized and rehydrated as described above.
Rehydrated sections were stained for 8 minutes in Alcian blue solution (1g Alcian blue, 100 ml
3% acetic acid, pH 2.5) and rinsed in running tap water for 2 minutes. Afterwards, 0.1%
Nuclear fast red solution (0.1g nuclear fast red, 5g Aluminum sulfate, 100ml distilled water)
was applied for 10 minutes followed by rinsing in running water for 3 minutes. Sections were
dehydrated, cleared and finally mounted in Entellan as described above.
PAS (Periodic Acid Solution) Staining
Sections were deparaffinized and hydrated to water. 0.5% periodic acid solution was applied
for 5 minutes. After rinsed in distilled water Schiff reagent was placed for 15 minutes. Washing
in lukewarm tap water for 5 minutes was followed by a counterstaining in Mayer's hematoxylin
for 1 minute. Again the sections were washed in tap water for 5 minutes, followed by dehydra-
tion and embedding using a synthetic mounting medium.
Real time PCR
Total RNA was isolated from tissue cultures of three donors after respective LPS- or LPS and
1,8-cineol treatment using the MasterPure RNA Purification Kit (Biozym Scientific GmbH,
Hessisch Oldendorf, Germany) followed by cDNA synthesis by First Strand cDNA Synthesis
Kit (Thermofisher, St. Leon-Rot, Germany) according to the manufacturer’s guidelines. qPCR
reactions were performed in technical triplicates using myBudget 5x EvaGreen QPCR-Mix II
(ROX) (BioBudget Technologies GmbH, Krefeld, Germany) according to the manufacturer’s
guidelines and assayed with a ABI PRISM 7000 Sequence detection system (Thermo Fisher Sci-
entific, Bonn, Germany). For primer sequences see Table 1.
Results
Cultured human nasal slices reveal intact ciliated surface and mucus-
filled goblet cells
To investigate potential effects of 1,8-cineol on mucus hypersecretion, we applied ex vivo cul-
tures of sliced human nasal turbinate tissue (Fig 1A and 1B). Determining the integrity of the
cultured nasal tissue, immunohistochemical stainings revealed the presence of acetyl-α-tubu-
lin-positive cilia in nasal slices cultured for 32 days (Fig 1C and 1D). Hematoxylin and eosin-
stained ciliated epithelial cells forming an intact ciliated surface (Fig 1E, arrowheads), goblet
cells (Fig 1E, arrows) as well as the presence of a basal membrane (Fig 1E, BM) further con-
firmed the integrity of the ex vivo cultured epithelium [25, 26]. In addition, cultured nasal tis-
sue showed no changes in Caspase 3-expression compared to inferior turbinate tissue,
suggesting unaffected viability of the cultured nasal tissue (S1 Fig). The presence of goblet cells
was further investigated using Alcian Blue-staining and Periodic acid-Schiff stain detecting
mucins [27]. As depicted in Fig 1E–1G, mucin-filled goblet cells were visible in cultivated nasal
slices (arrowheads), suggesting the applicability of the here established culture system to inves-
tigate potential effects of 1,8-cineol on mucus overproduction.
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Fig 1. Cultured human nasal slices show unimpaired epithelium containingmucus-filled goblet cells. A,B: Overview images of the established nasal
slice culture system showing sliced nasal tissue cultured in culture plate inserts within a 12-well-plate.C,D: Immunohistochemical staining revealed the
presence of acetyl-α-tubulin-positive cilia in nasal slice cultures. E: Hematoxylin and eosin-staining displayed the integrity of the ex vivo cultured epithelium
containing ciliated epithelial cells (arrowheads), goblet cells (arrows) and a basal membrane (BM). Scale Bar: 20 μm. F, G: Mucin-filled goblet cells (arrows)
were detected in cultivated nasal slices by Alcian Blue-staining and Periodic acid-Schiff stain. Scale Bar: 20 μm.
doi:10.1371/journal.pone.0133040.g001
Table 1. Primer Sequences.
target forward primer reverse primer
MUC5AC ACCTCTGCTCCTACAACCAGAACA GAAGTCCACGTCGAACCACTTTGT
MUC5B TATTCCACCTTTGACGGCACCTCT CTGCTCACCGGAATTTGGTCAAAC
MUC19 TCCCTAGGTGGAAGTGCAATGACA TCTGGATTCACTTCCGGTACTGCT
MUC2 AGCCCGGTTCTCCAGTTTATTCCT ATGAGCTGGTTGTGGATCTTCACG
TNFα AAGCCCTGGTATGAGCCCATCTAT AGGGCAATGATCCCAAAGTAGACC
doi:10.1371/journal.pone.0133040.t001
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Increased number of mucus-stuffed goblet cells in LPS-treated nasal
slice cultures is significantly reduced by co-treatment with 1,8-cineol
Simulating the presence of a bacterial cell wall, we treated cultivated nasal slices with LPS to
determine potential effects of 1,8-cineol on mucin overproduction during experimentally
induced late rhinosinusitis [28]. Here, Alcian Blue-staining revealed a highly increased number
of mucin-filled goblet cells in cultured tissue after LPS-treatment (Fig 2B, arrows) in contrast
to the untreated control approach (Fig 2A, arrows). Notably, the number of mucin-filled goblet
cells was decreased in cultured nasal slices treated with LPS and 1,8-cineol (Fig 2C, arrows).
Determining these effects in more detail, quantification of mucus-filled goblet cells revealed a
significantly increased number of mucin-filled cells after LPS-treatment, which was signifi-
cantly decreased after co-treatment with 1,8-cineol (Fig 2D). In addition, cultured nasal slices
co-treated with LPS and 1,8-cineol showed unchanged low numbers of Caspase 3-expressing
cells compared to untreated and LPS-treated cultures as well as to inferior turbinate tissue, sug-
gesting unaffected viability of the cultured nasal tissue (S1 Fig).
Exposure of nasal slice cultures to 1,8-cineol leads to significantly
decreased levels of MUC gene expression associated with reduced
activity of NF-κB
Investigating the effects of 1,8-cineol on mucus overproduction on a molecular level, we exam-
ined LPS as well as LPS- and 1,8-cineol-treated nasal slice cultures with real time PCR analysis
to determine levels of mucin gene expression. Here, co-treatment of nasal tissue with LPS and
1,8-cineol was significantly reduce the expression level of the mucin gene MUC2 in compari-
son to LPS-stimulated samples (Fig 3A). However, the expression levels of the mucin genes
MUC5AC and MUC5B were not significantly reduced in LPS-treated nasal slice cultures after
co-treatment with 1,8-cineol (Fig 3B, data not shown). Interestingly, the expression level of
MUC19 was also shown to be significantly reduced in slice cultures treated with LPS and
1,8-cineol in comparison to the LPS-treated approach (Fig 3C).
The transcription factor NF-κB is an essential regulatory factor of MUC gene-expression [29,
30]. Therefore, its activity was determined in ex vivo cultured nasal slices exposed to LPS. Nasal
slice cultures co-treated with LPS and 1,8-cineol exhibited significantly reduced expression levels
Fig 2. Increased number of mucus-filled cells in LPS-treated nasal slice cultures is significantly reduced by co-treatment with 1,8-cineol. A:
Representative Alcian Blue-staining of an untreated nasal slice culture revealed no increased amount of mucus-filled goblet cells (arrows). B: Representative
Alcian Blue-staining of LPS-treated nasal slices showed highly increased numbers of mucus-filled goblet cells (Arrows). C: Representative Alcian Blue-
staining of cultured nasal slices co-treated with LPS and 1,8-cineol displayed a highly decreased number of mucus-filled goblet cells (Arrows). Scale Bar:
20 μm. D: Quantification of total areas of Alcian Blue-stained slice cultures from four independent donors revealed a significantly increased number of mucin-
filled goblet cells in LPS-treated nasal slice cultures, which was significantly decreased after co-treatment with 1,8-cineol. *p < 0.5, **p < 0.01 were
considered significant (t-test); ns: not significant (t-test).
doi:10.1371/journal.pone.0133040.g002
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of the NF-κB-target gene TNFα in comparison to its LPS-dependent stimulation (Fig 3D).
Immunocytochemistry of LPS-treated nasal slice cultures revealed localization of NF-κB-p65
within the nucleus, further indicating NF-κB-activity (Fig 4A upper panels, arrows). Co-treat-
ment with LPS and 1,8-cineol resulted in reduced amounts of nuclear NF-κB-p65 (Fig 4A, lower
panels, arrows) and localization of NF-κB-p65 in the cytoplasm (Fig 4A, lower panels, arrow-
heads). Quantification of immunocytochemical analysis showed significantly increased numbers
of epithelial cells with cytoplasmic NF-κB-p65 in response to 1,8-cineol co-treatment in compar-
ison to the LPS-approach (Fig 4B). The significantly reduced NF-κB-activity is suggested to
result in the observed decrease in MUC2-gene expression levels (Fig 4C)[31].
Discussion
This study shows for the first time a reduction of mucus-production in ex vivo cultured human
nasal slices after 1,8-cineol treatment during experimental rhinosinusitis. Overproduction of
Fig 3. 1,8-cineol-treamtent leads to significantly decreased levels of MUC gene expression after their LPS-dependent stimulation. A: Real time PCR
analyses of nasal slice culture depicted increased levels of MUC2 after LPS-treatment, which were significantly reduced in LPS- and 1,8-cineol-treated
approaches. B: No significant changes in gene expression level of MUC5AC in nasal slice cultures after LPS- as well as LPS- and 1,8-cineol-treatment
shown by real time PCR.C: Real time PCR analyses revealed decreased levels of MUC19 in nasal slice cultures co-treated with LPS- and 1,8-cineol in
comparison to LPS-treated approaches. D: Real time PCR analyses showed decreased expression levels of TNFα in nasal slice cultures co-treated with
LPS- and 1,8-cineol compared to LPS-treated approaches. *p < 0.5, **p < 0.01 were considered significant (t-test); ns: not significant (t-test). GAPDH:
Glyceraldehyde 3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0133040.g003
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mucins is commonly associated with inflammatory airway diseases, such as rhinosinusitis (8)
and COPD ([2, 3]. In this study, we used LPS to mimic bacterial superinfection common dur-
ing late rhinosinusitis [28]. Exposure of ex vivo cultivated nasal slices to LPS resulted in signifi-
cantly increased density of mucin-filled goblet cells, reflecting the pathological situation during
rhinosinusitis [8]. In agreement with our findings, an increased mucin gene expression was
observed occurring in an LPS-dependent manner during the pathogenesis of cystic fibrosis
lung disease [30].
LPS was also described to be applicable for studying effects of 1,8-cineol during inflamma-
tion within several distinct cellular and animal models [24, 32, 33]. In our study, co-incubation
Fig 4. Nasal slice cultures exposed to 1,8-cineol show reduced activity of NF-κB. A Immunocytochemistry of LPS-treated nasal slice cultures revealed
nucleus localization of NF-κB-p65 (upper panels, arrows). Co-treatment with LPS and 1,8-cineol resulted in reduced amounts of nuclear NF-κB-p65 (lower
panels, arrows) and localization of NF-κB-p65 in the cytoplasm (lower panels, arrowheads). Scale bar: 20μm. B: Quantification of immunocytochemical
analysis showed significantly increased numbers of epithelial cells with cytoplasmic NF-κB-p65 after LPS and 1,8-cineol co-treatment in comparison to the
LPS-approach, indicating a significantly reduced NF-κB-activity. ***p < 0.001 was considered significant (t-test). C: Schematic view of NF-κB activating
MUC2 gene expression via binding to a κB-binding site in 5’ region of the MUC2 gene (31).
doi:10.1371/journal.pone.0133040.g004
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of nasal slice cultures with LPS and 1,8-cineol led to a significantly decreased number of
mucin-filled goblet cells. These observations further highlight the previously suggested role of
1,8-cineol in controlling mucus hypersecretion by cytokine inhibition [32]. In accordance to
our findings, Bastos and colleagues likewise reported in 2011 indications for the prevention of
mucus accumulation in OVA-challenged guinea pigs by 1,8-cineol [34]. Emphasizing the clini-
cal relevance of the presented data, Kehrl and coworkers demonstrated the successful applica-
tion of 1,8-cineol for treating rhinosinusitis in a randomized, double blind, placebo-controlled
trial with 152 patients [18].
Similar to physiological conditions, we found LPS-stimulated gene expression levels of
MUC2 and MUC19 to be significantly decreased after 1,8-cineol-treatment. Although
MUC5AC and MUC5B are also mainly involved in mucus production [5], MUC2 expression
is strongly associated with inflammatory airway diseases [11, 12, 30]. MUC2 was described to
be inducible by TNFα in human airway epithelial cells [35] as well as by LPS in a colon epithe-
lial cell line [30], bronchial explants and airway epithelial cells [23]. MUC2 expression is exclu-
sively found in goblet cells [8] and regulated by the transcription factor NF-κB [29, 30], which
activates MUC2 gene expression by binding to a κB-binding site in 5’ region of the MUC2
gene [31] (Fig 4). Recently, our group demonstrated that 1,8-cineol strongly inhibits NF-κB-
activity by reducing nuclear translocation of NF-κB-p65, which in turn resulted in strongly
attenuated expression of pro-inflammatory NF-κB target genes [24]. In particular, 1,8-cineol
significantly reduced the expression of TNFα [24], the major regulator of rhinosinusitis disease
mediation [21]. Using a mouse model of LPS-induced acute lung injury, Zhao and colleagues
validated the NF-κB-associated reduction of inflammation after 1,8-cineol-treatment [33].
Accordingly, 1,8-cineol also led to a reduced NF-κB-activity in ex vivo cultivated nasal slices in
the present study, suggesting the observed reduced mucus-production and gene expression of
MUC2 occurs in an NF-κB-dependent manner.
Kerschner and coworkers demonstrated upregulated expression levels of MUC19 in
response to pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα) in the
middle ear epithelium [36]. The present study further extends these findings by showing for
the first time an increased MUC19-expression within a model system of bacteria-induced rhi-
nosinusitis. Similar to MUC2, we show reduced MUC19 expression after 1,8-cineol-treatment
in association with significantly attenuated NF-κB-activity.
Here, we could demonstrate a 1,8-cineol-dependent reduction of mucus-production and
particularly MUC19 and MUC2 gene expression in ex vivo cultured human nasal slices in a
novel model for experimental rhinosinusitis (Fig 5). Given the NF-κB-dependent regulation of
MUC2 gene expression [31] and the observed reduction of NF-κB-activity, the effects of
1,8-cineol on mucus production and MUC2/MUC19 gene expression likely occur in a NF-κB-
dependent manner.
Conclusion
Treatment of rhinosinusitis, COPD or bronchial asthma strongly requires the reduction of
mucus overproduction, a hallmark of inflammatory airway diseases. For the first time our find-
ings demonstrate a 1,8-cineol-dependent reduction of mucus-production and expression of the
NF-κB target gene MUC2 which was associated with a reduced NF-κB-activity in ex vivo cul-
tured human nasal slices. This system represents a novel model for experimental rhinosinusitis.
The beneficial effects of 1,8-cineol on mucin overproduction presented here suggest novel ther-
apeutic medical approaches and may broaden the fields of application of 1,8-cineol. Therefore,
topical application of 1,8-cineol may offer a therapeutic approach to reduce bacteria-induced
mucus hypersecretion.
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Supporting Information
S1 Fig. 1,8-cineol-treatment does not affect viability of the nasal slice cultures. In compari-
son to inferior turbinate tissue (upper panels), cultured nasal slices showed unchanged low
amounts of apoptotic Caspase 3-expression cells (lower panels). Treatment of nasal slice cul-
tures with LPS as well as co-treatment with LPS and 10-4M 1,8-cineol did not result in
increased amounts of Caspase 3-expressing cells compared to untreated control.
(TIF)
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